Assessing concentration in the monoclonal antibody innovation market: A patent-based study
The concentration in the mAb innovation market is higher than the concentration in the market for chemical drugs innovations. Our findings also indicate that expertise in mAbs development and production is concentrated in a few countries. Additionally, our study identified that a few key players from high-income countries are driving innovation in the mAb market.
Authors
- Leonardo Costa Ribeiro (ORCID: https://orcid.org/0000-0002-7772-9313)
- Jeff Gow (ORCID: https://orcid.org/0000-0002-5726-298X)
- Kenya Noronha (ORCID: https://orcid.org/0000-0002-7174-6710)
- Mônica Viégas Andrade (ORCID: https://orcid.org/0000-0002-6821-1598)
- Khorshed Alam (ORCID: https://orcid.org/0000-0003-2232-0745)
- André Soares Santos (ORCID: https://orcid.org/0000-0002-2856-7100)
Institutions
- Universidade Federal de Minas Gerais (BR)
- University of Southern Queensland (AU)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1371/journal.pone.0320864
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00